NM_000546.6(TP53):c.451C>A (p.Pro151Thr) AND not provided

Germline classification:: Pathogenic/Likely pathogenic (2 submissions)
Last evaluated:: Mar 4, 2025
Review status:: 2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV000520731.5

Allele description [Variation Report for NM_000546.6(TP53):c.451C>A (p.Pro151Thr)]

NM_000546.6(TP53):c.451C>A (p.Pro151Thr)

Gene:

TP53:tumor protein p53 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

17p13.1

Genomic location:

Preferred name:

NM_000546.6(TP53):c.451C>A (p.Pro151Thr)

HGVS:

NC_000017.11:g.7675161G>T
NG_017013.2:g.17390C>A
NM_000546.6:c.451C>AMANE SELECT
NM_001126112.3:c.451C>A
NM_001126113.3:c.451C>A
NM_001126114.3:c.451C>A
NM_001126115.2:c.55C>A
NM_001126116.2:c.55C>A
NM_001126117.2:c.55C>A
NM_001126118.2:c.334C>A
NM_001276695.3:c.334C>A
NM_001276696.3:c.334C>A
NM_001276697.3:c.-27C>A
NM_001276698.3:c.-27C>A
NM_001276699.3:c.-27C>A
NM_001276760.3:c.334C>A
NM_001276761.3:c.334C>A
NP_000537.3:p.Pro151Thr
NP_000537.3:p.Pro151Thr
NP_001119584.1:p.Pro151Thr
NP_001119585.1:p.Pro151Thr
NP_001119586.1:p.Pro151Thr
NP_001119587.1:p.Pro19Thr
NP_001119588.1:p.Pro19Thr
NP_001119589.1:p.Pro19Thr
NP_001119590.1:p.Pro112Thr
NP_001263624.1:p.Pro112Thr
NP_001263625.1:p.Pro112Thr
NP_001263689.1:p.Pro112Thr
NP_001263690.1:p.Pro112Thr
LRG_321t1:c.451C>A
LRG_321:g.17390C>A
LRG_321p1:p.Pro151Thr
NC_000017.10:g.7578479G>T
NM_000546.4:c.451C>A
NM_000546.5:c.451C>A
P04637:p.Pro151Thr
p.P151T

Protein change:

P112T; PRO151THR

Links:

UniProtKB: P04637#VAR_005896; OMIM: 191170.0025; dbSNP: rs28934874

Molecular consequence:

NM_001276697.3:c.-27C>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001276698.3:c.-27C>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001276699.3:c.-27C>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_000546.6:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126112.3:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126113.3:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126114.3:c.451C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126115.2:c.55C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126116.2:c.55C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126117.2:c.55C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001126118.2:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276695.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276696.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276760.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001276761.3:c.334C>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:: none provided
Identifiers:: MedGen: C3661900

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV000617735	GeneDx	criteria provided, single submitter (GeneDx Variant Classification (06012015))	Likely pathogenic (Aug 24, 2018)	germline	clinical testing	Citation Link,
SCV004026691	Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital	criteria provided, single submitter (ACMG Guidelines, 2015)	Pathogenic (Mar 4, 2025)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV000617735

GeneDx

criteria provided, single submitter

(GeneDx Variant Classification (06012015))

Likely pathogenic
(Aug 24, 2018)

germline

clinical testing

Citation Link,

SCV004026691

Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital

criteria provided, single submitter

(ACMG Guidelines, 2015)

Pathogenic
(Mar 4, 2025)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	yes	not provided	not provided	not provided	not provided	not provided	clinical testing
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee.

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]

PMID:: 25741868
PMCID:: PMC4544753

Details of each submission

From GeneDx, SCV000617735.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

This variant is denoted TP53 c.451C>A at the cDNA level, p.Pro151Thr (P151T) at the protein level, and results in the change of a Proline to a Threonine (CCC>ACC). This variant has been observed in two individuals with early-onset breast cancer, one of whom had a family history of sarcoma and adrenocortical carcinoma (Vahteristo 2001, Maxwell 2015). Although this variant is reported as having non-functional transactivation in the International Agency for Research on Cancer TP53 database based on functional assays by Kato et al. (2003), and Monti et al. (2011) also found a significant reduction in transactivation activity, this variant was not found to cause a dominant-negative effect and only had a slight impact on growth suppression (Monti 2011, Kotler 2018). TP53 Pro151Thr was not observed in large population cohorts (Lek 2016). This variant is located in the DNA binding domain (Bode 2004). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on the currently available evidence, we consider TP53 Pro151Thr to be a likely pathogenic variant.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	yes	not provided	not provided	not provided		not provided	not provided	not provided	not provided

From Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, SCV004026691.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Apr 12, 2026

ClinVar

Relating variation to medicine